Navigation Links
Simbionix USA Corporation Announces the Appointment of Mr. Paul Jensen as General Manager for its Growing eLearning and Content Business
Date:9/9/2009

CLEVELAND, Ohio and DENVER, Colorado, September 9 /PRNewswire/ -- Simbionix USA Corporation, a global leader in simulation and training products for clinical professionals, today announced the appointment of Mr. Paul Jensen as the new General Manager for Simbionix's eLearning and Content business.

Mr. Jensen is an information services executive with extensive experience in building innovative information products and services for a variety of professional markets including education and corporate training. He was responsible for the learning management system for Aplia, a leading Web-based homework solution for higher education, and he created the first eLearning product strategy for Thomson Learning. Most recently, Mr. Jensen held several senior management roles with Wolters Kluwer, a global leader in information services and publishing, including responsibility for enterprise-wide strategies and business priorities for online content delivery systems. He earned his MBA, with honors, from Columbia Business School.

"Over the previous four months we were involved in an intensive, nationwide recruitment process to find the ideal person to lead our growing eLearning and Content business, and we are very pleased to have Paul join Simbionix," said Gary Zamler, Simbionix's CEO. "In order to meet the growing training and performance improvement needs of our global customers, Simbionix now offers a full range of integrated training solutions including virtual reality simulations, online courseware and learning management systems under our MentorLearn(TM) umbrella of products and services. Paul's talent, proven leadership, experience in identifying global trends and commercializing new e-Learning products and services, as well as in the delivery of online content, will be another building block in Simbionix's exponential growth and success in these areas of the global training and performance improvement market."

About Simbionix USA Corporation

Simbionix is the leader in the development and delivery of innovative and effective virtual reality simulation products and solutions for clinical education and training of medical professionals. The products are designed to accelerate best-practice medical training, advance clinical performance, and improve patient safety.

The Simbionix product line includes the ANGIO Mentor(TM) line for endovascular procedures, LAP Mentor(TM) line for laparoscopic surgical procedures, GI Mentor(TM) for upper and lower gastrointestinal procedures and the URO Mentor(TM) for urological procedures. In addition, Simbionix distributes the HystSim(TM) for hysteroscopic procedures. Each simulation platform is a leading simulator in the relevant clinical area.

Simbionix simulation products have been validated in several scientific studies and the company cooperates closely with both industry and leading medical institutions to develop the most advanced simulators for the training and assessment of medical professionals.

    Contact:
    Gary Zamler
    CEO
    Simbionix
    Tel: +1-216-229-2040
    gary@simbionix.com



'/>"/>
SOURCE Simbionix
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Simbionix and Johnson & Johnson LLC Announce a Distribution Agreement for Russia and the CIS Countries
2. Simbionix Increases Product Offerings for OB/GYN Physicians
3. Glen C. Williams Joins eLearning Sales Team for Simbionix, Heading up Chicago Office
4. New Colorectal Module From Simbionix Advances Laparoscopic Cancer Treatment
5. William E. Lewandowski to Lead Simbionix US Marketing Team in Simbionixs Strategic Expansion in the US Market
6. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
7. Simbionix Launches Innovative Patient-Specific Simulation
8. Simbionix Releases Powerful New Learning Management System With Enhanced True Assessment System(TM)
9. Simbionix Takes Non-Invasive GYN Surgical Training to the Next Level
10. 2007 a "Record Year" for Successful Validation Studies of Simbionix Simulators
11. eBioscience Corporation Acquires NatuTec GmbH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- NetworkNewsWire Editorial Coverage  ... Cancer remains one of the ... care systems, in terms of costs and resources. However, as ... development of innovative and efficient therapies that demonstrate higher chances ... of cancer treatments, a growing number of patients receiving immuno-oncology ...
(Date:3/22/2017)... N.Y. , March 22, 2017 Regeneron Pharmaceuticals, ... the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to ... the U.K. Biobank resource. The initiative will enable researchers to ... new medicines for a wide range of serious and life ... ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... 22, 2017   Boston Biomedical , an industry ... to target cancer stemness pathways, today announced its Board ... as Chief Executive Officer, effective April 24, 2017. ... Li , M.D., FACP, who has led Boston Biomedical ... his leadership, Boston Biomedical has grown from a "garage ...
Breaking Biology Technology:
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
Breaking Biology News(10 mins):